<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bleeding Academic Research Consortium definition for bleeding</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bleeding Academic Research Consortium definition for bleeding</h1>
<div class="graphic"><div class="figure"><div class="ttl">Bleeding Academic Research Consortium definition for bleeding</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Type 0</td> </tr> <tr> <td class="indent1">No bleeding</td> </tr> <tr> <td class="subtitle1_single">Type 1</td> </tr> <tr> <td class="indent1">Bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a health care professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a health care professional</td> </tr> <tr> <td class="subtitle1_single">Type 2</td> </tr> <tr> <td class="indent1">Any overt, actionable sign of hemorrhage (eg, more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: (1) requiring nonsurgical, medical intervention by a health care professional, (2) leading to hospitalization or increased level of care, or (3) prompting evaluation</td> </tr> <tr> <td class="subtitle1_single">Type 3</td> </tr> <tr> <td class="subtitle2_single">Type 3a</td> </tr> <tr> <td class="indent1">Overt bleeding plus hemoglobin drop of 3 to &lt;5 g/dL* (provided hemoglobin drop is related to bleed)</td> </tr> <tr class="divider_bottom"> <td class="indent1">Any transfusion with overt bleeding</td> </tr> <tr> <td class="subtitle2_single">Type 3b</td> </tr> <tr> <td class="indent1">Overt bleeding plus hemoglobin drop ≥5 g/dL* (provided hemoglobin drop is related to bleed)</td> </tr> <tr> <td class="indent1">Cardiac tamponade</td> </tr> <tr> <td class="indent1">Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid)</td> </tr> <tr class="divider_bottom"> <td class="indent1">Bleeding requiring intravenous vasoactive agents</td> </tr> <tr> <td class="subtitle2_single">Type 3c</td> </tr> <tr> <td class="indent1">Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal)</td> </tr> <tr> <td class="indent1">Subcategories confirmed by autopsy, imaging, or lumbar puncture</td> </tr> <tr> <td class="indent1">Intraocular bleed compromising vision</td> </tr> <tr> <td class="subtitle1_single">Type 4: CABG-related bleeding</td> </tr> <tr> <td class="indent1">Perioperative intracranial bleeding within 48 hours</td> </tr> <tr> <td class="indent1">Reoperation after closure of sternotomy for the purpose of controlling bleeding</td> </tr> <tr> <td class="indent1">Transfusion of ≥5 units whole blood or packed red blood cells within a 48-hour period<sup>¶</sup></td> </tr> <tr> <td class="indent1">Chest tube output ≥2 L within a 24-hour period</td> </tr> <tr> <td class="subtitle1_single">Type 5: Fatal bleeding</td> </tr> <tr> <td class="subtitle2_single">Type 5a</td> </tr> <tr class="divider_bottom"> <td class="indent1">Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious</td> </tr> <tr> <td class="subtitle2_single">Type 5b</td> </tr> <tr> <td class="indent1">Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation</td> </tr> </tbody></table></div><div class="graphic_lgnd">CABG indicates coronary artery bypass graft. Platelet tranfusions should be recorded and reported but are not included in these definitions until further information is obtatined about the relationship to oucomes. If a CABG-related bleed is not adjudicated as at least a type 3 severity event, it will be classified as not a bleeding event. If a bleeding event occurs with a clear temporal relationship to CABG (ie, within a 48-hour time frame) but does not meet type 4 severity criteria, it will be classified as not a bleeding event.</div><div class="graphic_footnotes">CABG: coronary artery bypass graft.<br/>* Corrected for transfusion (1 unit packed red blood cells or 1 unit whole blood = 1 g/dL hemoglobin).<br/>¶ Cell saver products are not counted.</div><div class="graphic_reference">Reproduced with permission from: Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123:2736. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id="graphicVersion">Graphic 77838 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
